AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLIANCE PHARMA PLC

Net Asset Value Jul 1, 2019

7478_rns_2019-07-01_0144a779-41cb-43f3-a91a-85b0a96d8cc0.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9316D

Alliance Pharma PLC

01 July 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Block Listing Six Monthly Return

Name of applicant: ALLIANCE PHARMA PLC
Names of schemes: a)   The Alliance Pharma plc Approved Share Option Plan 2005

b)   The Alliance Pharma plc Share Option Plan 2006

c)   The Alliance Pharma plc Company Share Option Plan 2015
Period of return: From: 28 December 2018 To: 28 June 2019
Number of securities originally admitted at date of admission: 25,000,000 ordinary shares of 1p each

28 June 2017
Balance of unallotted securities under schemes from previous return: a)   1,091,266

b)   15,345,688

a)   2,049,922
Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for): a)   Nil

b)   Nil

c)   Nil
Less:  Number of securities issued/allotted under schemes during period: a)   107,725

b)   Nil

c)   823,825
Equals:  Balance under schemes not yet issued/allotted at end of period: a)   983,541

b)   15,345,688

c)   1,226,097
Name of contact: Chris Chrysanthou, Company Secretary
Telephone number of contact: Tel. +44 (0)1249 705166

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLRURORRKRANOUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.